Physician profile
Shuaib Mohyuddin
NPI 1285682211
$13,154.35
in general payments reported to CMS, 2019-2025
59 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $2,556 · 2021: $2,621 · 2022: $1,803 · 2023: $1,150 · 2024: $1,925 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,697.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,135.79 | 2019-2025 | |
| Lilly USA, LLC | $928.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $918.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $903.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $737.65 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.51 | 2019-2025 | Jardiance, Jascayd, Synjardy |
| Novartis Pharmaceuticals Corporation | $486.21 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $420.83 | 2019-2022 | |
| Astellas Pharma US INC | $404.01 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $392.34 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $378.09 | 2020-2025 | Evenity, Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $282.27 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.90 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $252.11 | 2019-2025 | Gardasil 9, Capvaxive |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuaib Mohyuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.